Cargando…

Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options

Cancer cachexia is a complex multifactorial syndrome whose hallmarks are weight loss due to the wasting of muscle tissue with or without the loss of adipose tissue, anorexia, systemic inflammation, and multi-organ metabolic alterations, which negatively impact patients’ response to anticancer treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Panebianco, Concetta, Villani, Annacandida, Potenza, Adele, Favaro, Enrica, Finocchiaro, Concetta, Perri, Francesco, Pazienza, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916111/
https://www.ncbi.nlm.nih.gov/pubmed/36768173
http://dx.doi.org/10.3390/ijms24031849
_version_ 1784886048275300352
author Panebianco, Concetta
Villani, Annacandida
Potenza, Adele
Favaro, Enrica
Finocchiaro, Concetta
Perri, Francesco
Pazienza, Valerio
author_facet Panebianco, Concetta
Villani, Annacandida
Potenza, Adele
Favaro, Enrica
Finocchiaro, Concetta
Perri, Francesco
Pazienza, Valerio
author_sort Panebianco, Concetta
collection PubMed
description Cancer cachexia is a complex multifactorial syndrome whose hallmarks are weight loss due to the wasting of muscle tissue with or without the loss of adipose tissue, anorexia, systemic inflammation, and multi-organ metabolic alterations, which negatively impact patients’ response to anticancer treatments, quality of life, and overall survival. Despite its clinical relevance, cancer cachexia often remains an underestimated complication due to the lack of rigorous diagnostic and therapeutic pathways. A number of studies have shown alterations in gut microbiota diversity and composition in association with cancer cachexia markers and symptoms, thus supporting a central role for dysbiosis in the pathogenesis of this syndrome. Different tools of microbiota manipulation, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been investigated, demonstrating encouraging improvements in cachexia outcomes. Albeit pioneering, these studies pave the way for future research with the aim of exploring the role of gut microbiota in cancer cachexia more deeply and setting up effective microbiota-targeting interventions to be translated into clinical practice.
format Online
Article
Text
id pubmed-9916111
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99161112023-02-11 Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options Panebianco, Concetta Villani, Annacandida Potenza, Adele Favaro, Enrica Finocchiaro, Concetta Perri, Francesco Pazienza, Valerio Int J Mol Sci Review Cancer cachexia is a complex multifactorial syndrome whose hallmarks are weight loss due to the wasting of muscle tissue with or without the loss of adipose tissue, anorexia, systemic inflammation, and multi-organ metabolic alterations, which negatively impact patients’ response to anticancer treatments, quality of life, and overall survival. Despite its clinical relevance, cancer cachexia often remains an underestimated complication due to the lack of rigorous diagnostic and therapeutic pathways. A number of studies have shown alterations in gut microbiota diversity and composition in association with cancer cachexia markers and symptoms, thus supporting a central role for dysbiosis in the pathogenesis of this syndrome. Different tools of microbiota manipulation, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been investigated, demonstrating encouraging improvements in cachexia outcomes. Albeit pioneering, these studies pave the way for future research with the aim of exploring the role of gut microbiota in cancer cachexia more deeply and setting up effective microbiota-targeting interventions to be translated into clinical practice. MDPI 2023-01-17 /pmc/articles/PMC9916111/ /pubmed/36768173 http://dx.doi.org/10.3390/ijms24031849 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Panebianco, Concetta
Villani, Annacandida
Potenza, Adele
Favaro, Enrica
Finocchiaro, Concetta
Perri, Francesco
Pazienza, Valerio
Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title_full Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title_fullStr Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title_full_unstemmed Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title_short Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
title_sort targeting gut microbiota in cancer cachexia: towards new treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916111/
https://www.ncbi.nlm.nih.gov/pubmed/36768173
http://dx.doi.org/10.3390/ijms24031849
work_keys_str_mv AT panebiancoconcetta targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT villaniannacandida targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT potenzaadele targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT favaroenrica targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT finocchiaroconcetta targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT perrifrancesco targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions
AT pazienzavalerio targetinggutmicrobiotaincancercachexiatowardsnewtreatmentoptions